Along these lines, NF-κB is activated in CML cells despite Bcr-Abl inhibition, downstream of, for example, IL-1 [15] or TNF signaling [50]. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.